Quanterix Q3 2026 earnings

QTRX · 2026-11-09 08:07 BMO ET · 8-K on SEC · 10-Q on SEC

Revenue grew sequentially despite prior-year comparisons, but the company remains unprofitable with a widening adjusted EBITDA loss.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$34.97M-13.1%+6.3%Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 38.6% (prior 39.5%, change -0.9 pp)
  • Operating expenses $35.99M (+32.4% YoY)
  • One-offs in the quarter Impairment and restructuring costs: $171K; Acquisition and integration related costs: $0; Earnout recorded as compensation expense: $0
  • Effective tax rate 1.3% (prior-year 6.9%, year-to-date -0.3%)
  • Non-GAAP bridge Adds back depreciation and amortization, stock-based compensation, acquisition and integration costs, earnout, changes in contingent liabilities, and impairment and restructuring costs.

KPIs

MetricActualPrior quarterPrior yearChange
Cash and marketable securities$80.7M$96.9M$100.0M-16.2M
Adjusted gross margin47.4%47.9%45.9%-0.5 pp

Guidance

MetricGuidePrior guideChange
Total revenues$142-146M$142-146MNo change
Adjusted gross margin48-50%48-50%No change
Cash balance at year-endApproximately $70MApproximately $70MNo change

What drove it

  • Revenue story Product revenue increased sequentially to $25.19M, while service and other revenue decreased sequentially to $9.36M.
  • EPS story Net loss per share improved to $-0.46 from $-0.73 YoY, driven by lower operating expenses and interest income.
  • One-off check Impairment and restructuring costs of $171K (non-GAAP) and $171K (GAAP) for the quarter.

The good

  • Revenue grew 6.3% sequentially
  • Adjusted gross margin improved 150 bps YoY
  • Cash balance remains strong at $80.7M

The bad

  • Net loss widened to $21.59M YoY
  • Adjusted EBITDA loss widened to $12.17M YoY
  • Service and other revenue decreased sequentially

The ugly

  • none

Open questions

  • The release mentions 'continued market softness' but does not quantify it.
  • The company does not provide a specific date for achieving cash-flow break-even.
Full release

Quanterix (QTRX) earnings release, November 9, 2026

Quanterix Corp (QTRX) · Form 8-K, Item 2.02 · Filed · SEC filing

Quanterix Releases Financial Results for the Third Quarter of 2026

Reports $35.0 million in revenue, up 6.3% sequentially, and $80.7 million of cash and marketable securities

Initiatives to accelerate commercial effectiveness position the Company for growth in rest of 2026 and going forward

BILLERICA,

Mass. – November 9, 2026

-- Quanterix Corporation

(NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the third quarter ended September 30, 2026.

“We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses. The actions we initiated last quarter to improve commercial performance, including reorganizing our teams and adding experienced leadership and discipline, should accelerate our execution in the fourth quarter and beyond,” said Everett Cunningham, President & CEO of Quanterix.

He added, “We are confident about the benefits and differentiated positioning of our research tools and diagnostics businesses, especially with new commercial leadership focused on sustained growth. Our continued innovation in ultra-sensitive protein-detection in blood and high plex spatial analysis in tissue provides us with market advantages in targeted discovery and translational research. Lastly, we have now established a strong foundation for Quanterix in diagnostics, through strategic investments and partnerships, enabling us to focus on achieving key milestones in Alzheimer’s disease testing, with our single-site Alzheimer’s disease five biomarker blood test.”

Third Quarter Financial Highlights

• Revenue of $35.0 million, an increase of 6.3% compared to the second quarter.

• GAAP gross margin of 38.6% down 90 basis points (bps) compared to the prior year. Adjusted gross margin (non-GAAP) of 47.4% up 150 bps vs. the prior year.

• Net loss of $21.6 million, an improvement of 35.6% compared to the prior year. Adjusted EBITDA (non-GAAP) loss of $12.2 million a decline of 2.4% vs. the prior year.

• The Company ended the third quarter with $80.7 million of cash, cash equivalents, marketable securities, and restricted cash.

Operational and Business Highlights

• Quanterix finished building its senior management team for planned growth, especially in the diagnostics business. As previously announced, Jim Gute was named Chief Commercial Officer in mid-August, and Dr. Yuri Fesko was named the company’s first Chief Medical Officer in September, bringing considerable expertise in clinical and regulatory management, which is already benefiting the Company’s commercial efforts.

• Additional milestones to advance clinical adoption of blood-based Alzheimer’s disease testing were announced, including expanded insurance coverage. Beginning November 1, 2026, traditional Medicaid members and state employees in Florida can receive coverage for qualifying blood-based biomarker tests, including Quanterix’s LucentAD® Complete, when medical necessity criteria are met.

• Quanterix added two new commercial partnerships with key regional full-service clinical reference labs, Sherman Abrams Lab in New York and TruPath in Mississippi. These relationships are underway and generating opportunities for diagnostics revenue, adding to existing partnerships.

• New regulatory approvals advanced access to neurology biomarker testing in China based upon Quanterix’s HD-X and SR-X instruments and testing kits for four biomarkers. Innovita Biological Technology Co., a leading Chinese diagnostics company, is broadening access to blood biomarker testing in China, as part of our strategy to bring our SIMOA®

-

-powered diagnostics capabilities to large markets worldwide by working with strong regional commercial partners.

• Quanterix launched additional assay menu options for its SIMOA® platform, as part of a commitment to expanding research tools on new biomarkers for Alzheimer’s and other neurodegenerative diseases.

• Underscoring Quanterix’s leadership in spatial biology through its Content Innovation Engine, the Company announced three new spatial products at the European Society for Spatial Biology meeting in September. The PhenoCode™ 2.0 Molecular Barcoding Kit is now in full commercial release, enabling researchers to barcode virtually any antibody in applications spanning immuno-oncology, neuroscience and other areas. The TIME panel, providing a broader view of the tumor immune microenvironment, and a high-plex ADC panel that enables co- measurement of ADC target expression alongside tumor immune contexture within a single tissue section, addressing demand for combination biology readouts, are both shipping in early 2027.

• Quanterix’s Accelerator Lab is now accepting requests for custom ADC panel development, widening access to the strength of its ADC combination biology fully managed service for biopharma and translational teams.

2026 Business Outlook

Quanterix is narrowing its expectations for total revenues to $142-146 million. The Company continues to expect adjusted gross margins (non-GAAP) in a range of 48-50%. Quanterix now expects to end 2026 with a cash balance of approximately $70 million, and no debt.

Conference Call

In conjunction with this announcement, the Company will host a conference call today, November 9, 2026, at 8:30 AM ET. The dial-in number for USA & Canada is Toll-Free (800) 715-9871 or (646) 307-1963 and the conference ID is 3290884.

Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website at https://ir.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.

About Quanterix... (truncated)rug development. Its SIMOA® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics. Learn more at www.quanterix.com.

Financial statements

Income Statement

Three Months Ended September 30, — (amounts in thousands, except per share data, unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenues:
Product revenue25,19326,15174,14963,723
Service and other revenue9,35914,03628,75229,971
Collaboration and license revenue422461,3941,348
Total revenues34,97440,233104,29595,042
Costs of goods sold and services:
Cost of product revenue15,44716,68445,20838,619
Cost of service and other revenue6,0277,64817,34715,683
Total costs of goods sold and services21,47424,33262,55554,302
Gross profit13,50015,90141,74040,740
Operating expenses:
Research and development7,3728,00922,51627,126
Selling, general and administrative28,45338,04385,57599,561
Impairment and restructuring costs1717,17446,94014,844
Total operating expenses35,99653,226155,031141,531
Loss from operations-22,496-37,325-113,291-100,791
Other income (expense), net:
Interest income6631,4482,3167,408
Change in fair value of contingent liabilities595582,0173,952
Other income (expense), net-65-17821,117-68
Loss before income taxes-21,303-35,997-87,841-89,499
Income tax benefit (expense)-2882,480-2275,466
Net loss-21,591-33,517-88,068-84,033
Net loss per common share, basic and diluted-0.46-0.73-1.87-2.04
Weighted-average common shares outstanding, basic and diluted47,38846,06047,17341,243

Income Statement

Three Months Ended September 30, — (amounts in thousands except percentages, unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net loss-21,591-33,517-88,068-84,033
Interest income-663-1,448-2,316-7,408
Income tax benefit (expense)288-2,480227-5,466
Depreciation and amortization6,4325,43118,1699,618
Stock-based compensation expense (1)3,7845,46912,17316,303
Acquisition and integration related costs (2)7,3152,00415,032
Earnout recorded as compensation expense (3)2298,129
Changes in contingent liabilities (4)-595-58-2,017-3,952
Impairment and restructuring costs (5)1717,17449,44214,844
Income from contract termination (6)-21,596
Adjusted EBITDA (non-GAAP)-12,173-11,885-31,982-36,933
Total revenues34,97440,233104,29595,042
Adjusted EBITDA margin (non-GAAP) (adjusted EBITDA as a % of revenue)-34.8-29.5-30.7-38.9%

Income Statement

Three Months Ended September 30, — (amounts in thousands except percentages, unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Gross profit13,50015,90141,74040,740
Purchase accounting impact on inventory and property and equipment (1)2053560735
Amortization of acquired intangible assets (2)2,8572,5328,5932,993
Adjusted gross profit (non-GAAP)16,56218,46850,94043,768
Total revenues34,97440,233104,29595,042
Gross margin (gross profit as % of total revenues)38.6%39.5%40.0%42.9%
Adjusted gross margin (non-GAAP) (adjusted gross profit as % of total revenues)47.4%45.9%48.8%46.1%
Total operating expenses35,99653,226155,031141,531
Purchase accounting impact on property and equipment (1)-326-212-1,518-212
Amortization of acquired intangible assets (2)-78-73-206-73
Acquisition and integration related costs (3)-7,315-2,004-15,032
Earnout recorded as compensation expense (4)-229-8,129
Impairment and restructuring costs (5)-171-7,174-49,442-14,844
Adjusted total operating expenses (non-GAAP)35,42138,223101,861103,241
Loss from operations-22,496-37,325-113,291-100,791
Purchase accounting impact on inventory and property and equipment (1)5312472,125247
Amortization of acquired intangible assets (2)2,9352,6058,7993,066
Acquisition and integration related costs (3)7,3152,00415,032
Earnout recorded as compensation expense (4)2298,129
Impairment and restructuring costs (5)1717,17449,44214,844
Adjusted loss from operations (non-GAAP)-18,859-19,755-50,921-59,473

Balance Sheet

September 30, 2026 — (amounts in thousands, except per share data, unaudited)

September 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents35,86429,839
Marketable securities41,49588,393
Accounts receivable, net of allowance for expected credit losses27,19729,972
Inventory44,82154,763
Prepaid expenses and other current assets8,7389,290
Total current assets158,115212,257
Restricted cash3,3523,341
Property and equipment, net18,29023,672
Intangible assets, net102,408131,787
Goodwill26,376

Cash Flow

Nine Months Ended September 30, — (amounts in thousands, unaudited)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-88,068-84,033
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense18,1699,618
Credit losses on accounts receivable478284
Accretion of marketable securities-333-1,851
Operating lease right-of-use asset amortization2,4382,058
Stock-based compensation expense12,52516,303
Impairment46,7697,269
Change in fair value of contingent liabilities-2,017-3,952
Recognition of off-market liability-13,975-5,678
Other operating activity-441-76
Changes in assets and liabilities:
Accounts receivable1,9997,901
Inventory9,6904,204
Prepaid expenses and other current assets2072,198
Accounts payable-3,365-3,537
Accrued compensation and benefits, accrued expenses, and other current liabilities-8,585-5,847
Deferred revenue-9,497-526
Net change in other operating assets and liabilities-5,422-5,127
Net cash used in operating activities-39,428-60,792
Cash flows from investing activities:
Purchases of marketable securities-16,669-45,658
Proceeds from sales and maturities of marketable securities63,755183,389
Purchases of property and equipment-258-2,710
Acquisitions, net of cash acquired-93,229
Net cash provided by investing activities46,82841,792
Cash flows from financing activities:
Deferred acquisition payments-1,439
Principal payments on financing leases-260-106
Proceeds from common stock issued under stock plans525930
Payments for employee taxes withheld on stock-based compensation awards-71-1,010
Net cash used in financing activities-1,245-186
Net increase in cash, cash equivalents, and restricted cash6,155-19,186
Effect of exchange rate changes on cash, cash equivalents, and restricted cash-1191,501
Cash, cash equivalents, and restricted cash at beginning of period33,18059,319
Cash, cash equivalents, and restricted cash at end of period39,21641,634

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix’s future business outlook, operations, strategy and financial performance, including statements related to our expectations about revenue growth, market advantages in translational research, opportunities for diagnostics revenue, expanded reimbursement for and access to blood biomarker testing, and under the header “2026 Business Outlook.” Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities with respect to Quanterix’s future business, operations, strategy and financial performance: risks related to the impact of changes in U.S. government policies, including impacts of tariffs and reductions in federal research funding; risks associated with the anticipated timing for launch of, and features of, Quanterix’s next-generation instruments to upgrade its existing platforms; risks related to Quanterix’s ability to improve existing diagnostics and develop new diagnostic tests and tools; risks related to Quanterix’s ability to successfully penetrate the diagnostics market; risks related to Quanterix’s ability to retain and expand its customer base and achieve sufficient market acceptance of its products; risks related to the ability of Quanterix’s contract manufacturers and suppliers to reliably and consistently manufacture and supply our instruments; risks that Quanterix may fail to realize the anticipated benefits from its recent acquisitions of Emission, Inc. and Akoya Biosciences Inc.; risks that Quanterix’s estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect; risks related to Quanterix’s ability to maintain effective internal control over financial reporting and disclosure controls and procedures; and risks related to defects or other quality issues in Quanterix’s products that could lead to unforeseen costs, product recalls, adverse regulatory actions, negative publicity and litigation. Additional factors that could cause results to differ materially from those described above can be found in the periodic reports filed by Quanterix with the SEC, including the “Risk Factors” sections contained therein, which are available on the SEC’s website at www.sec.gov.

All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix’s underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix anticipates. Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Quanterix does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.

FINANCIAL HIGHLIGHTS

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.